Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease

A fixed duration of venetoclax-rituximab (VenR) resulted in a significant benefit of both PFS and in the attainment of an undetectable minimal residual disease (uMRD) compared with bendamustine-rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients. The 2018 International...

Descripción completa

Detalles Bibliográficos
Autores principales: Benedetti, Edoardo, Baratè, Claudia, Mavilia, Fabrizio, Bramanti, Emilia, Morganti, Riccardo, Guerri, Valentina, Cervetti, Giulia, Capochiani, Enrico, Bertaggia, Ilaria, Stella, Salvatore Massimo, Traverso, Ginevra, Bruno, Benedetto, Galimberti, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003523/
https://www.ncbi.nlm.nih.gov/pubmed/36902559
http://dx.doi.org/10.3390/jcm12051772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003523/
https://www.ncbi.nlm.nih.gov/pubmed/36902559
http://dx.doi.org/10.3390/jcm12051772

Ejemplares similares